Chilton Capital Management LLC Decreases Position in IQVIA Holdings Inc. $IQV

Chilton Capital Management LLC trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 45.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 219 shares of the medical research company’s stock after selling 182 shares during the quarter. Chilton Capital Management LLC’s holdings in IQVIA were worth $35,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Canada Pension Plan Investment Board raised its position in shares of IQVIA by 7.3% in the 1st quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company’s stock valued at $810,069,000 after purchasing an additional 312,807 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of IQVIA by 45.7% in the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock worth $448,686,000 after buying an additional 798,534 shares during the last quarter. Nordea Investment Management AB lifted its stake in shares of IQVIA by 41.7% during the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock worth $326,274,000 after buying an additional 606,391 shares during the period. American Century Companies Inc. increased its position in shares of IQVIA by 26.8% in the 1st quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company’s stock valued at $253,695,000 after acquiring an additional 304,258 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in IQVIA by 2.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company’s stock worth $251,852,000 after acquiring an additional 40,699 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on IQV shares. Cowen reissued a “buy” rating on shares of IQVIA in a report on Wednesday, July 23rd. Truist Financial increased their price target on shares of IQVIA from $209.00 to $235.00 and gave the stock a “buy” rating in a report on Wednesday, July 23rd. Evercore ISI upped their price objective on shares of IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a report on Wednesday, October 8th. Robert W. Baird raised their target price on shares of IQVIA from $159.00 to $196.00 and gave the stock a “neutral” rating in a report on Wednesday, July 23rd. Finally, William Blair reaffirmed an “outperform” rating on shares of IQVIA in a report on Wednesday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $234.57.

IQVIA Stock Up 0.3%

IQV stock opened at $220.64 on Monday. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $225.91. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The firm’s fifty day moving average is $194.47 and its 200 day moving average is $171.56. The firm has a market cap of $37.51 billion, a PE ratio of 31.93, a P/E/G ratio of 2.42 and a beta of 1.32.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.